About FDA

The Office of Prescription Drug Promotion (OPDP)

(formerly Division of Drug Marketing, Advertising and Communications - DDMAC)

Get e-mail updates when this information changes Sign up for updates on The Office of Prescription Drug Promotion by e-mail

Office Location:

10903 New Hampshire Ave., Building 51, Room 3203
Silver Spring, MD 20993-0002

Phone and Fax Numbers:

Phone: 301-796-1200
Fax: 301-847-8444 or 301-847-8445


"To protect the public health by ensuring that prescription drug information is truthful, balanced, and accurately communicated.  This is accomplished through a comprehensive surveillance, enforcement, and education program, and by fostering better communication of labeling and promotional information to both healthcare professionals and consumers." 

OPDP Issues Draft Guidance on Providing Regulatory Submissions in Electronic and Non-Electronic Format

On April 21, 2015, OPDP issued a draft guidance for public comment entitled Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs. This draft guidance describes the various types of submissions of promotional materials and general considerations for submissions. In addition, this draft guidance discusses the specific aspects of submission of promotional materials using module 1 of the electronic Common Technical Document (eCTD) using version 3.3 or higher of the us-regional-backbone file to OPDP or to the Center for Biologics Evaluation and Research's Advertising and Promotional Labeling Branch (APLB) under section 745(a) of the Federal Food, Drug, and Cosmetics Act.  Within 24 months of the publication of the final version of this guidance, all submissions under section 745(a) must be made electronically using the eCTD specifications.

OPDP Issues Revised Draft Guidance on Brief Summary and Adequate Directions for Use Requirements

On February 6, 2015, OPDP issued a revised draft guidance for public comment entitled Brief Summary and Adequate Directions for Use: Disclosing Risk Information in Consumer-Directed Print Advertisements and Promotional Labeling for Human Prescription Drugs. The revised draft guidance responds to stakeholder requests for specific guidance on disclosure of risk information to consumers and incorporates recent social science research results. This revised draft guidance pertains to what is commonly known as the “brief summary requirement” for consumer-directed print advertisements and to the requirement that certain information be included with consumer-directed print promotional labeling pieces for human prescription drugs and biologics.  The guidance revises the January 2004 draft guidance entitled Brief Summary: Disclosing Risk Information in Consumer-Directed Print Advertisements.

OPDP releases internet and social media guidances

Technology is continually changing, but FDA’s commitment to public health does not. In today’s world, a tremendous amount of information exchange occurs on the web and through social media. On June 17, 2014, FDA’s Office of Prescription Drug Promotion released two highly-anticipated guidances related to the November 2009 Part 15 public hearing discussion topics that provide FDA’s current views and recommendations for medical product companies who wish to use the Internet/social media. FDA received public comments on these guidances during two open comment periods.  FDA is currently reviewing the comments and plans to update the documents accordingly.  To see the guidances and learn more, please visit our social media guidances webpage.

New Form FDA-2253

The Office of Prescription Drug Promotion (OPDP) has a new Form FDA-2253[PDF] and new instructions [PDF].  Visit the OPDP Form FDA-2253 submissions page for additional information.

Risk Communication Advisory Committee; Notice of Meeting

Information About What OPDP Reviewers Do

OPDP reviewers have responsibility for reviewing prescription drug advertising and promotional labeling to ensure that the information contained in these promotional materials is not false or misleading. They engage in a variety of tasks to perform this responsibility, including: providing written comments to pharmaceutical sponsors on proposed promotional materials to ensure clear and unambiguous communication of the laws and regulations relating to prescription drug promotion; reviewing complaints about alleged promotional violations; initiating enforcement actions on promotional materials that are false or misleading; comparing the product labeling and promotional materials of various closely related products to ensure that the regulatory requirements are consistently and equitably applied; traveling to major medical meetings and pharmaceutical conventions to monitor promotional exhibits and activities; and acting as a liaison between OPDP and other divisions within the FDA on promotional issues.  Interested in a position at OPDP?

Important Information About Submissions

OPDP reminds all companies who are engaging in DTC advertising of prescription drugs that the requirements of section 906 of the Food and Drug Administration Amendments Act of 2007 (FDAAA) went into effect on March 25, 2008. Section 906 of FDAAA mandates that published direct-to-consumer advertisements for prescription drugs include the following statement printed in conspicuous text: "You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088."

Proposed Regulatory Submissions in Electronic and Non-Electronic Format

Please see the draft guidance for information on electronic (including eCTD) and non-electronic submissions. Please note that implementation for the new eCTD M1 is still pending. Please refer to the eCTD webpage for details and timing of implementation.

For technical questions on eCTD format for CDER, please refer to the eCTD webpage or contact esub@fda.hhs.gov.  For questions regarding the guidance or eCTD submissions to OPDP, please contact OPDPeCTD@fda.hhs.gov.

Truthful Prescription Drug Advertising and Promotion (Bad Ad Program)
The Prescriber's Role - Recognize and Report

FDA's educational outreach program is designed to educate healthcare providers about the role they can play in helping the agency make sure that prescription drug advertising and promotion is truthful and not misleading.

The "Bad Ad" Program is administered by the agency's Office of Prescription Drug Promotion in the Center for Drug Evaluation and Research. It will help healthcare providers recognize misleading prescription drug promotion and provide them with an easy way to report this activity to the agency.

Truthful Prescription Drug Advertising and Promotion (Bad Ad Program)

Information about the status of the DTC user fee program enacted under the Food and Drug Administration Amendments Act of 2007 (FDAAA) is posted at the

Direct-to-Consumer (DTC) Television User Fee Program Documents

Page Last Updated: 04/22/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.